🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 21 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
25/08/2025 10,54 10,76 10,11 10,15 -3,61% 6,14% 632.900
22/08/2025 10,55 11,00 10,48 10,53 +0,48% 4,93% 726.900
21/08/2025 10,07 10,61 9,92 10,48 +3,87% 6,85% 593.800
20/08/2025 10,03 10,23 9,95 10,09 +0,30% 2,79% 569.100
19/08/2025 10,50 10,50 9,81 10,06 -3,92% 6,57% 872.100
18/08/2025 10,49 10,75 10,37 10,47 +0,77% 3,67% 523.800
15/08/2025 10,04 10,51 9,97 10,39 +4,84% 5,38% 884.000
14/08/2025 9,92 10,06 9,73 9,91 -1,49% 3,33% 740.200
13/08/2025 9,79 10,23 9,74 10,06 +4,03% 5,01% 974.500
12/08/2025 9,22 9,77 9,22 9,67 +5,57% 5,97% 995.400
11/08/2025 9,01 9,32 8,88 9,16 +1,10% 4,83% 1.031.500
08/08/2025 9,27 9,44 8,96 9,06 -2,37% 5,12% 751.000
07/08/2025 9,97 10,74 9,22 9,28 -2,21% 15,25% 1.478.600
06/08/2025 9,42 9,53 9,09 9,49 -0,63% 4,67% 709.800
05/08/2025 9,24 9,60 9,10 9,55 +3,47% 5,47% 778.000
04/08/2025 9,17 9,30 8,99 9,23 +0,76% 3,38% 425.900
01/08/2025 9,01 9,27 8,84 9,16 +0,33% 4,77% 805.000
31/07/2025 9,35 9,45 9,06 9,13 -3,18% 4,16% 702.200
30/07/2025 9,82 9,93 9,26 9,43 -1,87% 6,77% 544.900
29/07/2025 9,89 9,89 9,51 9,61 -2,44% 3,84% 800.500
28/07/2025 10,22 10,34 9,78 9,85 -3,71% 5,48% 1.304.500
25/07/2025 9,88 10,24 9,61 10,23 +3,65% 6,38% 713.700
24/07/2025 9,74 9,97 9,54 9,87 +1,23% 4,41% 591.500
23/07/2025 9,33 9,89 9,19 9,75 +6,44% 7,50% 790.700
22/07/2025 9,37 9,46 9,14 9,16 -1,08% 3,42% 492.400
21/07/2025 9,24 9,50 9,17 9,26 +1,20% 3,57% 599.800
18/07/2025 9,54 9,62 9,13 9,15 -2,87% 5,19% 437.300
17/07/2025 9,23 9,61 9,23 9,42 +1,73% 4,12% 948.500
16/07/2025 9,18 9,38 9,09 9,26 +2,55% 3,16% 494.300
15/07/2025 9,68 9,68 8,97 9,03 -6,42% 7,33% 649.900